%0 Journal Article %T Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort %+ Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)) %+ AP-HP - Hôpital Bichat - Claude Bernard [Paris] %+ Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425) %+ Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)) %+ CIC - HEGP (CIC 1418) %+ CArdiovasculaire Rénal Transplantation nEurovasculaire [Paris] (DMU CARTE) %+ Hôpital Européen Georges Pompidou [APHP] (HEGP) %+ Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 (UGSF) %+ Service des Maladies Infectieuses et Tropicales [CHRU Nancy] %+ Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ) %+ Centre Hospitalier Universitaire [Grenoble] (CHU) %+ Centre Hospitalier Universitaire de Reims (CHU Reims) %+ Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) %+ CHU Pontchaillou [Rennes] %+ ARN régulateurs bactériens et médecine (BRM) %+ Centre d'Investigation Clinique [Rennes] (CIC) %+ CIC Cochin Pasteur (CIC 1417) %+ CHU Saint-Antoine [AP-HP] %+ Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)) %+ Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris] %+ French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ) %+ Hopital Saint-Louis [AP-HP] (AP-HP) %+ Hôpital Foch [Suresnes] %+ Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ) %+ Centre Hospitalier Gustave Dron [Tourcoing] %+ European Atherosclerosis Society [Göteborg, Sweden] (EAS) %+ CHU Pointe-à-Pitre/Abymes [Guadeloupe] %+ Université des Antilles - UFR des sciences médicales Hyacinthe Bastaraud (UA UFR SM) %+ Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille) %+ Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA) %+ Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane) %+ CHU de la Martinique [Fort de France] %+ Pathogenesis and Control of Chronic and Emerging Infections (PCCEI) %+ F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC) %+ CIC - CHU Bichat %+ Laboratoire Chrono-environnement (UMR 6249) (LCE) %A Ghosn, Jade %A Bachelet, Delphine %A Livrozet, Marine %A Cervantes-Gonzalez, Minerva %A Poissy, Julien %A Goehringer, François %A Gandonniere, Charlotte Salmon %A Maillet, Mylène %A Bani-Sadr, Firouzé %A Martin-Blondel, Guillaume %A Tattevin, Pierre %A Launay, Odile %A Surgers, Laure %A Dudoignon, Emmanuel %A Liegeon, Geoffroy %A Zucman, David %A Joseph, Cédric %A Senneville, Eric %A Yelnik, Cécile %A Roger, Pierre-Marie %A Faure, Karine %A Gousseff, Marie %A Cabié, André %A Duval, Xavier %A Chirouze, Catherine %A Laouénan, Cedric %Z The French COVID cohort is funded by the REACTing (REsearch & ACtion emergING infectious diseases) consortium, by a grant of the French Ministry of Health (PHRC n°20-0424), and by the ORCHESTRA project which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N°101016167. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. %< avec comité de lecture %@ 1198-743X %J Clinical Microbiology and Infection %I Elsevier for the European Society of Clinical Microbiology and Infectious Diseases %V 29 %N 2 %P 254.e7-254.e13 %8 2023-02 %D 2023 %R 10.1016/j.cmi.2022.08.028 %M 36191847 %K Cohort %K Emerging infectious diseases %K Moderate to severe COVID-19 %K Post-acute COVID-19 symptoms %K SARS-CoV-2 %Z Life Sciences [q-bio]/Human health and pathologyJournal articles %X Objectives - Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort. Methods - Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender. Results - We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale <57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%). Conclusions - One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men. %G English %2 https://u-picardie.hal.science/hal-03801797/document %2 https://u-picardie.hal.science/hal-03801797/file/Ghosn%20et%20al.%20-%202022%20-%20Prevalence%20of%20post-acute%20COVID-19%20symptoms%20twelve%20%20%281%29.pdf %L hal-03801797 %U https://u-picardie.hal.science/hal-03801797 %~ INSERM %~ UNIV-PARIS13 %~ UNIV-TLSE3 %~ UNIV-AG %~ UNIV-RENNES1 %~ UNIV-TOURS %~ CNRS %~ UNIV-PICARDIE %~ UNIV-FCOMTE %~ APHP %~ CHRONO-ENVIRONNEMENT %~ IFR140 %~ HL %~ U835 %~ CIC %~ CIC203 %~ IPLESP %~ UR1-UFR-SVE %~ UR1-HAL %~ UR1-SDV %~ UNIV-MONTPELLIER %~ TEST-UR-CSS %~ UNIV-RENNES %~ UNIV-LILLE %~ CHU-UNIV-PARIS5 %~ SORBONNE-UNIVERSITE %~ SORBONNE-UNIV %~ SU-MEDECINE %~ SU-MED %~ PCCI %~ SORBONNE-PARIS-NORD %~ UNIV-PARIS %~ UNIVERSITE-PARIS %~ UP-SANTE %~ SU-TI %~ UR1-BIO-SA %~ INFINITY %~ U-PICARDIE %~ AGIR-UPJV %~ ALLIANCE-SU %~ PCCEI-ANTILLES %~ UNIV-UT3 %~ UT3-INP %~ UT3-TOULOUSEINP %~ UM-2015-2021 %~ UM-EPE %~ TEST3-HALCNRS %~ TEST4-HALCNRS %~ CIC1417 %~ TEST5-HALCNRS